التفاصيل البيبلوغرافية
| العنوان: |
Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. |
| المؤلفون: |
Boussios, Stergios, Karihtala, Peeter, Moschetta, Michele, Abson, Charlotte, Karathanasi, Afroditi, Zakynthinakis-Kyriakou, Nikolaos, Ryan, Jake Edward, Sheriff, Matin, Rassy, Elie, Pavlidis, Nicholas |
| المصدر: |
Investigational New Drugs; Feb2020, Vol. 38 Issue 1, p181-193, 13p |
| مصطلحات موضوعية: |
ANTINEOPLASTIC agents, CANCER chemotherapy, DNA, DRUG synergism, ENZYME inhibitors, GENE expression, GENETIC mutation, PROTEINS, INVESTIGATIONAL drugs, OVARIAN epithelial cancer, PHARMACODYNAMICS |
| مستخلص: |
Summary: Epithelial ovarian cancer (EOC) accounts for nearly 90% of all ovarian malignancies. The standard therapeutic strategy includes cytoreductive surgery and neo (adjuvant) platinum-based chemotherapy. Relapse of advanced high grade serous ovarian cancer (HGSOC) is related to the development of drug resistance. A defective DNA damage response is a defining hallmark of HGSOC. Poly (ADP-ribose) polymerase (PARP) inhibitors exploit this deficiency through synthetic lethality and have emerged as promising anticancer therapies, especially in breast cancer gene (BRCA1 or BRCA2) mutation carriers. Apart from inducing synthetic lethality, PARP inhibitors have also been shown to trap PARP1 and PARP2 on DNA, leading to PARP-DNA complexes. This "PARP trapping" potentiates synergism between PARP inhibition and both alkylating agents and platinum-based chemotherapy. However, there are remarkable differences in the ability of PARP inhibitors to trap PARP, based on the size and structure of each separate molecule. Since monotherapy with PARP inhibitors is unlikely to induce cancer cell death in BRCA-proficient tumors, the efficacy of PARP inhibitors could be potentially optimized when combined with DNA-damaging agents, or with molecular targeted agents that also impair mechanisms of DNA repair. Olaparib, rucaparib, and niraparib have all obtained US Food and Drug Administration (FDA) and/or European Medicines Agency (EMA) approval in ovarian cancer in different settings. Veliparib does not yet have an approved label; nevertheless, there are currently promising results available in preclinical and early clinical settings. This comprehensive review summarizes the mechanism of action of veliparib and provides an overview of its early and ongoing clinical investigations. [ABSTRACT FROM AUTHOR] |
|
Copyright of Investigational New Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder